First line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients (MBC) presenting with de novo or recurrent disease.

Abstract

e11575 Background: Approximately 5-10% of breast cancer (BC) patients have metastases at the time of diagnosis (de novo stage IV), suggesting distinct biological and clinical implications as compar...